A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinumbased chemotherapy (chemo)

被引:2
作者
Gupta, S. [1 ]
Alhalabi, O. [2 ]
Bamias, A. [3 ]
Bellmunt, J. [4 ]
Castellano Gauna, D. E. [5 ]
Bedke, J. [6 ]
Friedlander, T. [7 ]
Garmezy, B. [8 ]
Grivas, P. [9 ]
Huddart, R. A. [10 ]
Necchi, A. [11 ]
Powles, T. B. [12 ]
Puente, J. [13 ]
Da Rosa, D. A. R. [14 ]
Wang, F. [15 ]
Lambertini, C. [16 ]
Andreev-Drakhlin, A. [17 ]
Fasso, M. [18 ]
Loriot, Y. [19 ]
机构
[1] Taussig Canc Ctr Cleveland Clin, Dept Med, Cleveland, OH USA
[2] Univ Texas MD Anderson Canc Ctr, GU Med Oncol Dept, Canc Med, Houston, TX USA
[3] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece
[4] Harvard Med Sch, Dept Med Oncol, Boston, MA USA
[5] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[6] Klinikum Stuttgart Katharinenhosp KH, Dept Urol, Stuttgart, Germany
[7] UCSF Univ Calif San Francisco, Med Oncol, San Francisco, CA USA
[8] Sarah Cannon Res Inst, Res, Nashville, TN USA
[9] Univ Washington, Seattle Canc Care Alliance, Med Oncol Dept, Seattle, WA USA
[10] Royal Marsden Hosp Inst Canc Res, Radiotherapy & Imaging Dept, Sutton, Surrey, England
[11] IRCCS Osped San Raffaele, Dept Med Oncol, Milan, Italy
[12] St Bartholomews Hosp Barts Hlth NHS Trust, Dept Oncol, London, England
[13] Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain
[14] Grupo Oncoclin, Oncol, Sao Paulo, Brazil
[15] F Hoffmann La Roche AG Switzerland, Med Oncol, Basel, Switzerland
[16] F Hoffmann La Roche & Cie AG, Oncol Biomarker Dev, Basel, Switzerland
[17] Genentech Inc, GU, San Francisco, CA USA
[18] Genentech Inc, PDMA, San Francisco, CA USA
[19] Inst Gustave Roussy, Dept Canc Med, Villejuif, France
关键词
D O I
10.1016/j.annonc.2023.09.2827
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
2409TiP
引用
收藏
页码:S1225 / S1225
页数:1
相关论文
empty
未找到相关数据